A remote-controlled CAR-T for safer immunotherapy
Peer-Reviewed Publication
Updates every hour. Last Updated: 29-May-2026 13:15 ET (29-May-2026 17:15 GMT/UTC)
The Epstein-Barr virus (EBV) can cause certain types of cancer or autoimmune diseases, but how the body controls this common viral infection is largely unknown. Researchers at the University Hospital Bonn (UKB) and the University of Bonn have now identified genetic and non-genetic factors that help the body fight EBV. To do this, they evaluated genome sequencing data, which is actually intended for characterizing the human genome, in a new way. Using the new technique, they were able to estimate the amount of EBV in the blood and find correlations in large health data sets – for example, an increased viral load in people with HIV infections, but also in smokers. There were also indications of new genes that play key roles in EBV immunity. Their findings have now been published in the renowned journal Nature.
Centromeres play virtually the same central role across the entire tree of life: They ensure the faithful segregation of chromosomes during cell division. Yet the striking diversity in centromere architecture – from large, repeat-rich DNA arrays to the minimalistic “point” centromeres in yeast – combined with their rapid evolution has puzzled scientists for decades. A research team led by Andrea Musacchio, Director at the Max Planck Institute of Molecular Physiology in Dortmund, and Jef Boeke from the NYU Grossmann School of Medicine have now solved the enduring mystery about the yeast centromere’s origin and evolution. They have identified a “proto-point” centromere that bridges the gap between the actual tiny “point” centromere and its more elaborate ancestor that incorporated fragments of parasitic DNA. This discovery reveals one of the most dramatic evolutionary transitions at DNA level
Transcatheter aortic valve implantation (TAVI) is a minimally invasive procedure that is used to treat narrowing of the aortic valve (aortic stenosis).
The feasibility and safety of same-day hospital discharge was studied in selected patients after day-case TAVI based on defined eligibility criteria.
Around 1 in 5 patients were successfully discharged on the same day as their day-case TAVI procedure, without increased risk of adverse outcomes.
Given the benefits for patients and for the healthcare system, same-day discharge after day-case TAVI may be implemented more widely in clinical practice.
Researchers at the Icahn School of Medicine at Mount Sinai have reported promising findings that may help redefine treatment for patients with muscle-invasive bladder cancer, a potentially aggressive form of the disease traditionally treated with surgical removal of the bladder. The study, published in the Proceedings of the National Academy of Sciences, demonstrates that ultra-sensitive testing of tumor-derived DNA in blood and urine may help identify patients who can safely preserve their bladder without compromising cancer outcomes.